Akut limfoid leukémia (ALL): vizsgálatok itt: Kína
169 trials · From ClinicalTrials.gov, checked 2026. november 16.. Ask the study team whether a trial fits you.
- No phaseTaking peopleUsing Multiparametric Flow Cytometry to Detect Peripheral Blood and Bone Marrow Leukaemia Stem Cells for Relapse Prediction in P-AML
- Where
- Beijing
- Életkor
- Up to 18 év
- People
- 283
- Run by
- Peking University People's Hospital
See details and how to joinNCT06452732 - Korai 1. fázisTaking peopleClinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies
- Where
- Hefei
- Életkor
- 18 év to 70 év
- People
- 19
- Run by
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07312630 - No phaseTaking peopleSafety and Feasibility of Sulforaphane to Promote Early Haematopoietic Recovery After Cord Blood Transplantation
- Where
- Tianjing
- Életkor
- 18 év and over
- People
- 36
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07297576 - No phaseTaking peopleCAV Regimen for R/R Ph- B-ALL
- Where
- Suzhou
- Életkor
- 15 év to 70 év
- People
- 36
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT05657652 - 2. fázisNot yet taking people in KínaBEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients
- Where
- Shanghai
- Életkor
- 18 év to 75 év
- People
- 23
- Run by
- Ruijin Hospital
See details and how to joinNCT07301138 - 2. fázisTaking peopleEfficacy and Safety of Low-dose Chemotherapy Plus Immuno-targeted Drugs in Newly Diagnosed Adult Ph- B-ALL
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 53
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06387121 - 1. fázisTaking peopleClinical Study of LV009 Injection for the Treatment of Hematologic and Lymphoid Malignancies
- Where
- Suzhou
- Életkor
- 18 év to 70 év
- People
- 10
- Run by
- PersonGen BioTherapeutics (Suzhou) Co., Ltd.
See details and how to joinNCT07284927 - 1/2. fázisTaking peopleSupCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
- Where
- Tianjin
- Életkor
- 18 év to 70 év
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07153068 - 1. fázisTaking peopleTo Observe the CD7-targeted CAR-T Therapy in the Treatment of MRD Positive T-ALL/LBL Post Allo-HSCT
- Where
- Beijing
- Életkor
- 3 év to 80 év
- People
- 18
- Run by
- Peking University People's Hospital
See details and how to joinNCT07280494 - Korai 1. fázisNot yet taking people in KínaAutologous Bedside CD19 CAR T-cell Therapy for B-ALL
- Where
- Chengdu
- Életkor
- 18 év to 70 év
- People
- 50
- Run by
- The General Hospital of Western Theater Command
See details and how to joinNCT07277504 - 2. fázisTaking peopleA Multicenter Study of CAR-T Cells in Primary Ph+All
- Where
- Hangzhou
- Életkor
- 18 év and over
- People
- 50
- Run by
- Zhejiang University
See details and how to joinNCT07252336 - Korai 1. fázisNot yet taking people in KínaAllogeneic UCB-derived CAR-T for B-ALL
- Where
- Chengdu
- Életkor
- 18 év to 70 év
- People
- 50
- Run by
- The General Hospital of Western Theater Command
See details and how to joinNCT07256353 - 1/2. fázisTaking peopleAutologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
- Where
- Beijing, Chengdu, Shanghai
- Életkor
- 1 év to 70 év
- People
- 80
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT06316427 - 1/2. fázisTaking peopleA Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
- Where
- Beijing, Chengdu, Shanghai
- Életkor
- 1 év to 70 év
- People
- 54
- Run by
- Beijing GoBroad Hospital
See details and how to joinNCT07070323 - 2. fázisTaking peopleAssessment of Senl_B19 CAR-T Cells in Relapsed/Refractory CD19+ B-ALL
- Where
- Beijing
- Életkor
- 3 év to 25 év
- People
- 59
- Run by
- Hebei Senlang Biotechnology Inc., Ltd.
See details and how to joinNCT07244406 - 2. fázisTaking peopleInotuzumab Ozogamicin in the Treatment of MRD+ After HSCT of ALL
- Where
- Suzhou
- Életkor
- 15 év to 65 év
- People
- 42
- Run by
- Sheng-Li Xue, MD
See details and how to joinNCT05940961 - 1. fázisTaking peopleBlinatumomab and Auto-HSCT Sandwich Strategy as Consolidation Therapy for B-ALL
- Where
- Suzhou
- Életkor
- 15 év to 65 év
- People
- 4
- Run by
- The First Affiliated Hospital of Soochow University
See details and how to joinNCT06507514 - 3. fázisTaking peopleEfficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
- Where
- Guangzhou
- Életkor
- 18 év to 70 év
- People
- 154
- Run by
- Nanfang Hospital, Southern Medical University
See details and how to joinNCT07203352 - 1. fázisTaking peopleSafety Study of CC312 in Adult Patients With Relapsed/Refractory CD19 Positive B-cell Hematologic Malignancies
- Where
- Tianjin
- Életkor
- 18 év and over
- People
- 44
- Run by
- CytoCares Inc
See details and how to joinNCT06037018 - 1. fázisTaking peopleuCD7 CART for Relapsed or Refractory CD7 Positive Hematologic Malignancies
- Where
- Tianjin
- Életkor
- 18 év to 70 év
- People
- 12
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07109518 - 3. fázisTaking peopleNewly-diagnosed Pediatric Ph-positive B-ALL Protocol
- Where
- Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjin, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan
- Életkor
- 1 hónap to 18 év
- People
- 150 worldwide
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07152041 - 2/3. fázisTaking peopleNewly-diagnosed Pediatric T-cell ALL Protocol
- Where
- Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjin, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi’an
- Életkor
- 1 hónap to 18 év
- People
- 610 worldwide
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06855810 - 2/3. fázisTaking peopleNewly-diagnosed Low Risk Pediatric B-cell ALL Protocol
- Where
- Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hefei, Jinan, Nanchang, Nanjing, Nanning, Qingdao, Shanghai, Shenzhen, Suzhou, Tianjin, Wuhan, Xi’an
- Életkor
- 1 év to 18 év
- People
- 3000 worldwide
- Run by
- Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06882057 - 1. fázisNot yet taking people in KínaRN1201injection for Relapsed/Refractory CD19+/BCMA+ Hematologic Malignancies
- Where
- Nanjing
- Életkor
- 18 év and over
- People
- 27
- Run by
- The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07113496 - 1/2. fázisTaking peopleA Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)
- Where
- Chongqing, Guangzhou, Hefei, Nanchang, Nanjing, Tianjin, Wuhan, Xuzhou
- Életkor
- 3 év to 18 év
- People
- 47
- Run by
- Juventas Cell Therapy Ltd.
See details and how to joinNCT05667506